Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ? in Japan
In This Article:
-
QUVIVIQ? is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as insomnia
Tokyo, Japan and Cambridge, UK, 1 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that Nxera Pharma Japan Co., Ltd. (“NPJ”) has entered a new commercial partnership agreement with Shionogi & Co., Ltd. (“Shionogi”), regarding the distribution and sales for QUVIVIQ? (daridorexant 25 and 50 mg) in Japan. At the same time, the previous commercialization arrangement between NPJ and Mochida Pharmaceutical Co., Ltd. (“Mochida”) has been terminated. After negotiation between Shionogi and Mochida, Shionogi will be solely responsible for distribution and sales activities in Japan.
QUVIVIQ? is a novel dual orexin receptor antagonist, discovered by Idorsia Pharmaceuticals Ltd, that was approved by the Ministry of Health, Labour and Welfare of Japan (“MHLW”) for the treatment of adult patients with insomnia on 24 September 2024 (click here for announcement).
Under the terms of the new agreement, Nxera will be responsible for providing drug product for the Japanese market, and Shionogi will be exclusively responsible for distribution and sales in Japan. Nxera will receive an upfront payment and is eligible to receive royalties on net sales from Shionogi. Mochida Pharmaceutical Factory Co., Ltd., a Mochida’s subsidiary, will remain exclusively responsible for manufacturing of QUVIVIQ? in Japan. Upon the termination of the commercial agreement with Mochida, Nxera will make a one-off payment to Mochida.
Chris Cargill, President and CEO of Nxera Pharma, commented: “QUVIVIQ? has the potential to become a significant product for Nxera Pharma in Japan. Through its novel mechanism of action, it could provide a best-in-class treatment option to address a major national health issue that affects millions of individuals in Japan who suffer from insomnia. In Shionogi, we have secured a sales partner with the scale and expertise to rapidly address the full market opportunity and reach healthcare professionals and insomnia patients across the country. We will work together with Shionogi and Mochida to prepare for the launch of this innovative product for patients who suffer from insomnia as quickly as possible.”
–END–
About QUVIVIQ?
QUVIVIQ? (daridorexant) is a dual orexin receptor antagonist, that blocks the binding and activity of the wake-promoting neuropeptides known as orexins. In October 2022, daridorexant achieved positive Phase 3 top-line results in Japanese patients with insomnia and a New Drug Application was submitted in Japan in October 2023. Daridorexant is approved in the US and Europe and marketed in these territories under the brand name QUVIVIQ? by Idorsia Pharmaceuticals Ltd. Nxera Pharma has the Japanese and APAC (ex-China) rights for daridorexant following its acquisition of Idorsia Pharmaceuticals Japan Ltd and Idorsia Pharmaceuticals Korea Co., Ltd in 2023. QUVIVIQ? was co-developed in Japan by Nxera and Mochida Pharmaceutical Co. Ltd.